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Abstract 
Introduction: Our previous scoping review revealed limitations and inconsistencies in 
population surveys of chronic respiratory disease. Informed by this review, we piloted a cross-
sectional survey of adults in four South/South-East Asian low-and middle-income countries 
(LMICs) to assess survey feasibility and identify variables that predicted asthma or chronic 
obstructive pulmonary disease (COPD). 
Methods: We administered relevant translations of the BOLD-1 questionnaire with additional 
questions from ECRHS-II, performed spirometry and arranged specialist clinical review for a 
sub-group to confirm the diagnosis. Using random sampling, we piloted a community-based 
survey at five sites in four LMICs and noted any practical barriers to conducting the survey. 
Three clinicians independently used information from questionnaires, spirometry and 
specialist reviews, and reached consensus on a clinical diagnosis. We used lasso regression to 
identify variables that predicted the clinical diagnoses and attempted to develop an algorithm 
for detecting asthma and COPD.  
Results: Of 508 participants, 55.9% reported one or more chronic respiratory symptoms. The 
prevalence of asthma was 16.3%; COPD 4.5%; and ‘other chronic respiratory disease’ 3.0%. 
Based on consensus categorisation (n=483 complete records), "Wheezing in last 12 months" 
and "Waking up with a feeling of tightness” were the strongest predictors for asthma. For 
COPD, age and spirometry results were the strongest predictors. Practical challenges included 
logistics (participant recruitment; researcher safety); misinterpretation of questions due to 
local dialects; and assuring quality spirometry in the field.   
Conclusion: Detecting asthma in population surveys relies on symptoms and history. In 
contrast, spirometry and age were the best predictors of COPD. Logistical, language and 
spirometry-related challenges need to be addressed.  
Key words: asthma, chronic obstructive pulmonary disease, chronic respiratory disease, low- 
and middle-income countries, feasibility, questionnaire-based survey, spirometry. 
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Introduction 
Chronic Respiratory Diseases (CRD), most commonly asthma and chronic obstructive 
pulmonary disease (COPD), but also post-tuberculosis (TB) lung disease, bronchiectasis, 
interstitial lung disease and lung cancer, are common public health problems, with high 
prevalence and mortality rates globally, especially in low- and middle-income countries 
(LMICs) (1–4). Symptoms such as cough, phlegm, shortness of breath, chest tightness and 
wheeze, are disabling features of CRD that contribute to poor health-related quality of life (5), 
impact on family, work and societal roles, as well as using healthcare resources.  
Despite the high morbidity and mortality of CRD, awareness in LMICs is often low (6,7), with 
limited robust data on the true burden of disease in these countries (8), fuelled by debates 
over spirometric thresholds and predictive value of (largely non-specific) respiratory 
symptoms (9). Our previous scoping review of 281 CRD prevalence studies in LMICs identified 
several limitations that need to be addressed in future surveys (10). These included:  
1. Many surveys focused on detecting one condition (asthma or COPD); a few identified 
both, but hardly any mentioned other CRDs;  
2. Algorithms for making a clinical diagnosis (as opposed to recording lung function) were 
often not well formulated, especially for asthma;  
3. Restrictive lung conditions were rarely reported;  
4. The impact of CRD on the quality of life of individuals, or their social and healthcare 
burden were rarely reported. 
 
To understand how to resolve these evidence gaps, we conducted the Four-Country ChrOnic 
Respiratory Disease (4CCORD) pilot cross-sectional survey in five sites across four 
South/South-East Asian LMICs that were members of the NIHR Global Health Research Unit 
on Respiratory Health (RESPIRE) collaboration (11). The aim was to: 1) use all available 
information (survey, spirometry and clinical reviews and expert opinion) to reach consensus 
on a clinical diagnosis (asthma, COPD or ‘other CRD’); 2) identify variables that predict the 
clinical diagnoses of asthma or COPD, and 3) describe practical barriers and solutions to 
undertaking the survey in South/South-East Asian LMIC contexts. 




The cross-sectional survey was conducted in 2019 with local ethics approvals from respective 
Institute’s Ethics Committee or Review Board: Bangladesh Institute of Child Health Review 
Board BICH-ERC-02-06-2018 (Bangladesh); King Edward Hospital Research Center Ethics 
Committee: KEMHRC/RVM/EC/1191 (KEMHRC, India); Christian Medical Centre Institutional 
Review Board: IRB:11382 (OBSERVE) (CMC, Vellore, India) and Health Ministry’s Screening 
Committee, Government of India: 2018-0968; Medical Research & Ethics Committee: NMRR-
18-2923-42961 (IIR) (Ministry of Health, Malaysia); Institutional Review Board, International 
Research Force: IRFIRB042019 (Islamabad, Pakistan)]. The study was sponsored by the 
University of Edinburgh (ACCORD: Reference number: AC18111). Written informed consent 
was provided by all study participants. 
Study sites and population 
We recruited a random selection of 100 adults (18 years or over) at each of the five sites in 
four countries [Bangladesh (1); India (2); Malaysia (1); Pakistan (1)] for this cross-sectional 
survey. As this was a pilot study, we did not perform any formal sample size calculation. The 
characteristics of each site and the arrangements used to identify and recruit the participants 
are detailed in Table 1.  In summary, all sites used computer-generated random numbers, but 
Bangladesh and the two sites in India sampled from their existing Health and Demographic 
Surveillance System (HDSS) databases, whilst Malaysia and Pakistan used a staged process of 
randomly selecting first the areas/quarters, then (in Malaysia) the households, followed by 
individuals. 
Study questionnaire and clinical algorithm development  
In February 2019, the investigators from all five study sites and the University of Edinburgh 
conducted a workshop to determine the survey procedures. Informed by the preliminary 
findings of the scoping review, a range of validated questionnaires that had previously been 
used in LMICs to detect CRD were considered from the perspective of the conditions that we 
wished to identify and availability of local language versions. We decided to use the widely 
used BOLD-1 questionnaire (v3.1) (12), which detected COPD and other respiratory symptoms 
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and asked about TB and co-morbidities. The BOLD questionnaire (v3.1) was available in all 
languages used in these sites though problems obtaining/using the existing version meant 
that two sites (Bangladesh and Malaysia) undertook a new forward/backward translation (see 
Table 1). We added eight questions from the ECRHS-II questionnaire to detect asthma (13), 
and some sites had to translate these questions to their local language. For clarity, we refer 
to the final survey tool as the ‘RESPIRE study questionnaire’. 
Spirometry 
We performed spirometry using calibrated EasyOne Air spirometers (NDD Medical 
Technologies Inc, Andover MA, US). Reversibility was tested 15 minutes after administration 
of salbutamol 400µg (via metered dose inhaler and spacer).  Study staff from each site were 
trained by the team from the Pulmocare Research and Education (PURE) Foundation, Pune, 
India, to conduct spirometry according to the American Thoracic Society (ATS) and European 
Respiratory Society (ERS) guidelines (14). Quality checks of the spirometry data generated 
were performed by SS and DG (Senior respiratory physician and Spirometry Trainer at the 
PURE Foundation, Pune, India). Height and weight of the study participants were assessed by 
trained field workers using calibrated stadiometers and adult weighing scales to a precision 
of 0.1 centimetre or 0.1 kilogram, respectively. Age and ethnicity were self-reported by the 
participants. Age was recorded in completed years as the exact birth dates for some older 
participants were not available. We used Global Lung Function Initiative (GLI) 2012 reference 
values to calculate predicted values and lower limit of normal FEV1/FVC to define obstruction 
(15). We used ethnicity as “Southeast Asian” for the Malaysian dataset and "Other or Mixed" 
for the Bangladesh, Indian and Pakistan sites from the options in the online GLI calculator ( 
http://gli-calculator.ersnet.org/). 
Data collection and entry 
Data were collected at each site using interviewer-administered hard copies of the RESPIRE 
study questionnaire (resource limitations precluded development of bespoke data entry 
software in this pilot study). All data were entered into Microsoft Excel by the data entry 
operators. Spirometry data printouts with graphs were available for quality check and 
assessment. 
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Clinical assessment  
Anonymised data were shared with SS or DG who assessed the spirometry for quality and 
provided a provisional diagnosis based on spirometry and RESPIRE study questionnaire 
responses. SS/DG identified a list of participants in whom further information would be useful 
to clarify the diagnosis (specifically those with borderline or unclear spirometry, or where 
spirometry and symptoms were mismatched) and these participants were invited to a clinical 
examination with a local pulmonologist (or in Malaysia a family medicine specialist supported 
by a pulmonologist). The purpose of the clinical review was explained to the clinicians who 
were instructed to complete a clinical record sheet to document medical history, examine the 
participant and, at their discretion, repeat the spirometry or arrange any additional tests (See 
Supplementary File 1). All clinical findings were documented and the likely diagnosis recorded 
on a paper record sheet that was scanned and added to the study documentation.  
Consensus diagnosis categorisation 
Participants were categorised into one of ten diagnostic categories (defined in Table 2) 
determined by consensus of three primary care physicians with expertise in respiratory 
disease (NSH, EMK, HP). Each physician independently determined the diagnostic category 
based on the RESPIRE study questionnaire responses, spirometry print-outs, spirometry 
quality reports (from SS/DG) and the examining physician’s report (for selected participants). 
Disagreements were discussed, discrepancies resolved, and agreement reached between all 
three physicians. The consensus decision was then considered as the ‘gold standard’ 
diagnosis. 
Data/Statistical analysis 
We performed the analysis using the Stata v15 software and R software version 3.5.3 (16). 
Descriptive statistics were performed for all socio-demographic and ‘gold standard’ diagnosis 
categories.  
Logistic regression with Lasso model selection (based on the Schwarz Bayesian Criterion) was 
conducted using the HPGENSELECT procedure within SAS software version 9.4 (SAS Institute 
Inc., Cary, NC, USA) and was used to identify predictors of the “gold standard” diagnoses of 
(i) Asthma (symptoms/spirometry), and (ii) COPD. This method was used rather than standard 
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modelling methods to minimise the risk of overfitting and increased the predictive ability of 
our models (17). The variables shown in the table in Supplementary File 2 from the RESPIRE 
study questionnaire and spirometry reports were all included as explanatory variables in the 
Lasso regression models. We then used an internal validation method (bootstrapping) to 
validate the fitted regression models in R software version 4.0.4 (16,17). This involved 
bootstrapping the participant rows of the data, and then calculating the predicted values for 
each bootstrap dataset using the original fitted models. A calibration slope was then 
calculated for each bootstrap dataset via logistic regression of the outcome in the bootstrap 
dataset with the predicted values as the single explanatory variable (17). A mean calibration 
slope was then calculated for each fitted model, with a value close to one indicating a model 
with good calibration (17).  
The parameter estimates from the lasso regression model for asthma were used to calculate 
a risk score for diagnosing asthma. This involved calculating the sum of all relevant coefficients 
(except the intercept term) to calculate a diagnostic score R. For converting the risk score R 
to calculate a probability of asthma diagnosis, the probability of asthma P is 
P=exp(R+I)/(1+exp(R+I)), where R is the risk score, I is the intercept term, and exp is the 
exponential function. 
A Receiver Operator Characteristic (ROC) curve was constructed based on the model 
predicted values (risk score) derived from the lasso regression using the ROCit package (18) 
in R software. We also calculated the area-under-the-curve (AUC) of the ROC curve with 95% 
confidence intervals. 
Experiences and challenges of  conducting the survey 
To assess feasibility, each recruiting site documented their experiences and challenges during 
the preparatory phase, survey administration and conduct of the study. Major concerns or 
hurdles were collated for reporting, and any remedial action described. 
Patient and Public involvement 
Community Engagement and Involvement has been a core activity in all centres of the 
RESPIRE collaboration. Participants and other stakeholders have been actively engaged in 
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developing the RESPIRE research agenda, reviewing proposals, and are now involved in 
disseminating the findings of projects.  
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Results 
The socio-demographic characteristics of the 508 participants surveyed from the five sites are 
given in Table 3. Note that differences in characteristics between the sites (e.g. younger 
participants in Pakistan) may be explained by the small sample sizes in this feasibility study. 
177 (34.8%) had a clinical assessment. Overall, 283/508 (55.7%) reported one or more chronic 
respiratory symptoms, most commonly breathlessness on walking uphill (25%) or wheezing 
(21%). 33 (6.5%) reported breathing problems that interfered with daily activities. 
‘Gold standard’ diagnostic categorisation  
These are illustrated in the diagnostic algorithm (Figure 1), and listed in Table 2.  
In 12 of the 508 cases, no diagnostic category could be determined (mostly due to 
uninterpretable spirometry and/or inconsistent symptomatology) leaving 496 for analysis. 
Based on consensus categorisation, the prevalence of asthma was 16.3% (83/508), COPD was 
4.5% (23/508); and ‘other CRD’ 3.0% (15/508). Non-respiratory causes (e.g. heart 
disease/anaemia/obesity) were considered to be the cause of symptoms in 5.5% (28/508). 
Proportions varied by site, but as a pilot survey, we were underpowered to compare results 
by site, so these results are only provided in Supplementary File 3.  
Of the 83 participants diagnosed with asthma, only eight had obstructive spirometry with 
substantial reversibility (>400mls/15% specified by GINA as ‘confidently’ confirming an 
asthma diagnosis); 75 had a combination of symptoms, atopic co-morbidities and/or were 
diagnosed/treated for asthma (19). 42 had an isolated symptom that could have been due to 
asthma, but could have had other explanations (e.g. a single episode of a cough disturbing 
sleep could be due to a viral respiratory infection). In the absence of other CRD symptoms or 
abnormal spirometry, these were described as ‘isolated symptom (CRD unlikely)’ and were 
not included in the asthma category for further analysis. 
Based on GLI predictive values, 21.6% (110/508) had restrictive spirometry as defined by a 
post-bronchodilator FVC<80% and normal FEV1/FVC ratio.  Of these, 45 were asymptomatic.   
At the KEMHRC site, 27/106 (25.0%) participants had restrictive spirometry based on GLI 2012 
predictive values. This was reduced to 13 (12.2%) when locally calculated predictive values 
were used (20).   
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Predictors for asthma and COPD  
Lasso regression showed different variables were predictive of asthma and COPD (ten for 
asthma and three for COPD). The final models (linear predictors) for asthma and COPD are 
shown in Table 4. The models were based on a sample size of N=483 (out of the total 496 
cases analysed, 13 were dropped due to missing data for the variables).  
Predictors for asthma 
Within this sample, 76 participants had asthma (i.e. ‘asthma spirometry’ and ‘asthma 
symptoms’ according to gold-standard diagnosis) and 407 without asthma. The final logistic 
regression model of the gold-standard asthma diagnosis included ten distinct variables: “age”, 
“Did you have wheezing in the last 12 months?”, “Have you ever had trouble with breathing?”, 
“Woken up with a feeling of tightness” [ECRHS II], “Had an attack of shortness of breath (SoB) 
that came on following strenuous activity at any time in the last 12 months”, “Woken by an 
attack of coughing at any time in the last 12 months [ECRHS II]}”, nasal allergy, “pre-
FEV1%pred”, “post-FEV1%pred””, and “post-FVC%pred”. Of these  “Did you have wheezing in 
the last 12 months?”[BOLD I], “attack of shortness of breath following stenuous activity” 
[ECRHS II] and “Woken up with a feeling of tightness” [ECRHS II], were the strongest predictors 
of a gold-standard asthma diagnosis.   
Our internal (bootstrap) validation procedure for the asthma model (see Table 4) generated 
an average calibration slope of 1.17, which was close to 1. This indicates that the model has 
good calibration and should perform well when fitted to a new set of participants in future 
large-scale surveys and generate accurate asthma diagnostic risk scores. 
The parameter estimates from the lasso regression model for asthma (Table 4) were then 
used to calculate a risk score for diagnosing asthma. After omitting the intercept term, the 
diagnostic score R ranged from -0.56 to 3.48, with higher values indicating a greater 
probability of a gold-standard asthma diagnosis. 
A ROC curve was constructed for the diagnostic score  R based on the parameters in Table 4 
(see Figure 2). The area-under-the-ROC curve was low 0.66 (95% CI 0.59 to 0.3), and there 
was no clear optimum cut-off point identified from the ROC curve. However, separate cut-off 
points can be found which ensure the sensitivity and specificity are above 90% and allow us 
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to identify true asthma cases and true non-cases. Values of R above 2.33 were associated with 
a specificity of over 90%, allowing us to “rule in” an asthma diagnosis for all participants with 
R>2.33 in a future survey. Similarly, participants with R<1.35 are very unlikely to have asthma 
since the test sensitivity was over 90% for cut-off values below 1.35. In total, these two groups 
comprise approximately 31% of the overall study sample. However, there still remains 69% 
of participants with R scores in the range of 1.35 and 2.33 which it would have been difficult 
to classify, if only this diagnostic algorithm had been used.  
Predictors for COPD  
Regarding COPD, 22 participants had a gold standard COPD diagnosis and 461 did not. For 
COPD (n=483), three distinct variables were included in the model: “age”, “post-FEV1%pred”, 
and “post-FVC%pred”. “Post-FEV1/FVC ratio” is moderately correlated with ‘age’ (correlation 
coefficient -0.43) and, after adjusting for the three included variables, was not significant and 
was therefore not included in the final model.    
For the COPD model, the calibration slope was only 0.53. In a lasso regression model of COPD, 
including demographic and symptom questions and no spirometry (n=496), only age 
appeared in the final model (parameter estimate 0.066).  
Distinguishing asthma from COPD 
Fitting the same model to those with a diagnosis of asthma and COPD patients/participants 
only (n=98), the same predictors appeared in the final model as in Table 4, with the addition 
of pre-FVC%pred (see table in Supplementary File 4). Age and spirometry are useful not only 
to distinguish between participants with COPD and those without, but also to distinguish 
between those with COPD and those with an asthma diagnosis.  
Feasibility and learnings from conducting the survey  
Table 5 lists the barriers and challenges noted by the five sites. One particular challenge faced 
was the difficulties with the existing versions of the study questions which the researchers 
reported having to explain in the local dialect to some participants.   
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Discussion 
Over half the participants in our survey reported at least one chronic respiratory symptom. 
Based on a consensus categorisation, we estimated the prevalence of asthma as 16.3%; COPD 
4.5%; restrictive spirometry (based on GLI predictive values) 21.6%; and ‘other CRD’ 3.0%. 
5.5% were considered to have non-respiratory causes for their symptoms. Of the 83 
participants with asthma, only eight could be confirmed confidently with spirometry.  
Predicting an asthma diagnosis   
The fitted model for diagnosing asthma showed good calibration and performed well in the 
internal validation, so could be used to give an estimated probability of asthma in full-scale 
surveys. Unfortunately however, the low area-under-the-ROC curve meant that we could not 
identify a single cut-off point that would enable classification of all participants into binary 
categories of ‘asthma’ or ‘not asthma’.  However, the prediction model could determine sub-
populations that are either highly likely to have asthma or highly unlikely to have an asthma 
diagnosis, though this only classified about a third of the cases we detected by clinical 
consensus. 
Predicting a COPD diagnosis  
In contrast, COPD diagnosis appeared to be mainly dependent on spirometry. Questions 
based on respiratory symptoms did not appear to be helpful, only age was included in the 
final model with “post-FEV1%pred”, and “post-FVC%pred”. The (clinically surprising) omission 
of “post-FEV1/FVC ratio” is because the ratio is correlated with age. However, the models 
cannot be relied upon for predictive purposes as they showed poor calibration and exhibited 
substantial overfitting, even after using lasso regression. We suspect this was because of the 
low event rate for COPD in our study. The variables we identified as potential predictors of 
COPD need confirmation in future studies. 
Strengths and limitations 
This was a pilot cross-sectional survey, and the small numbers at each site mean that we were 
not powered for detecting prevalence in individual countries, though our data may be a guide 
for sample size calculations in future full-scale surveys. Notably, there were some differences 
in baseline characteristcs between sites that were likely to be due the small sample sizes in 
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this feasibility study (100 participants/site) rather than real differences in populations that 
would have been captured in a fully powered survey with approximately 1,000 
participants/site.   
The ‘gold standard’ categorisation was achieved with as much rigour as possible (three 
physicians independently making a diagnosis based on a range of available raw data (survey 
responses, spirometry with graphs, and a clinical history/examination/tests from a clinician in 
177 cases). Despite this, there may be some misdiagnoses, especially in categorising isolated 
symptoms when, despite consensus discussion, we could neither confirm nor conclusively 
rule out asthma (or other respiratory causes) in 45 participants. 
We limited our survey to adults, so we cannot comment on the challenge of detecting chronic 
respiratory disease in children.  
We intended to use existing translations of the widely used questions, so our findings aligned 
with major global surveys, though researchers reported difficulties with the ‘official’ or 
previously used translations which needed to be explained (or in two sites translated) into 
local dialects (see Table 5 for examples).     
Finally, the models developed have not been externally validated in other populations. 
Interpretation and implications for future surveys  
Despite a sample size commensurate with a pilot survey, our finding that half our participants 
reported at least one chronic respiratory symptom, and a quarter were categorised as having 
a CRD suggests a significant burden of disease in the populations surveyed.  These data were 
collected before the pandemic so were not affected by the rise in respiratory symptoms due 
to COVID-19. Other factors may be somatisation in contexts where mental health problems 
are stigmatised (21,22), and misunderstanding about translated words used to describe 
respiratory symptoms, diseases and health.  
Most published surveys focus on one disease (10). For example, in a recent systematic review, 
the global prevalence of COPD in adults 30-79 yrs was calculated as 7.7% (95% CI: 5.7-10.1) 
using the LLN-COPD definition (10.2% using FEV1/FVC <70%) (23). Our estimate of 4.7% (using 
LLN) is lower, in part because our wide recruitment strategy included adults between 18 and 
30 (unlikely to have significant COPD by virtue of age). In addition, this systematic review, in 
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common with many surveys (10), equated obstructive spirometry with a diagnosis of COPD. 
In line with GOLD 2020 guidelines, we took a clinical perspective and only categorised a 
participant as having COPD if they reported at least one relevant symptom (shortness of 
breath, cough, phlegm) (24). This will have overcome the ‘uneasy assumption’ in using 
FEV1/FVC <LLN, that COPD prevalence cannot be lower than 5% (25), as asymptomatic 
individuals with FEV1/FVC <LLN would not be categorised as COPD (as illustrated in Figure 1 
in which an asymptomatic participant with obstructive spirometry was characterised as 
‘unclear’). The limitation of not including symptom status is recognised (23), and standard 
questionnaires, e.g., BOLD (v3.1) (12) include questions on shortness of breath, persistent 
cough and interference with activities which could be incorporated in definitions. However, 
these symptom questions were not included in our final model after lasso model selection, 
and their application would need to be established in a larger sample. Cough and phlegm 
(along with age and peak flow) are included in the COLA ‘low cost screening tool’  derived and 
validated in Uganda (26). 
Detecting asthma in a survey is even more problematic. Our systematic review highlighted 
that the definitions of asthma used in surveys were usually based on symptoms or 
patient/participant-reported diagnosis and medication usage (10). The Global Burden of 
Disease define asthma as ‘a doctor’s diagnosis and wheezing in the past year’ (25) and 
reported a global prevalence of 3·6% (3·2% to 4.0%). Had we used ‘patient/participant-
reported doctor-diagnosed’, we would have identified a comparable prevalence of 21/508 
(4.1%). Spirometry was unhelpful, with only 8/83 (9.6%) demonstrating an increase in FEV1 
post-bronchodilation of >400mls (defined by GINA as enabling a ‘confident’ diagnosis) (19). 
Even using the lower threshold of >12% and 200mls (which is compatible with COPD (24)) 
only 18/83 (21.6%) of the participants we categorised as asthma had a spirometry confirmed 
diagnosis. Our ‘gold standard’ clinical diagnosis thus relied on symptoms and resulted in a 
prevalence of 16.3%, quadruple the GBD estimate. This reflects the recognised clinical 
difficulty of making a robust diagnosis of asthma in the absence of definitive tests, 
exacerbated in the context of a population survey because of the limited information 
available from a single assessment made when the participant may (or may not) be 
symptomatic. 
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Other causes of CRD are rarely reported in surveys (24). A recent systematic review reported 
interstitial lung disease, pulmonary sarcoidosis and pneumoconiosis (but not bronchiectasis, 
post-TB lung disease or cystic fibrosis) as having a very low prevalence of 0.07% (23). Our 
clinical ‘gold standard’ identified 3.0% as having symptoms probably due to CRD that was not 
asthma or COPD. Whilst further investigations would be required to establish the precise 
diagnoses, it is likely that these conditions are commonly overlooked in epidemiological 
studies and public health planning.  
A fifth (21.6%) of the spirometry was classified as ‘restrictive’ with FVC<80% and 
FEV1/FVC>LLN when using GLI 2012 normal values; 41% of whom were asymptomatic. This is 
likely to be an artefact of using incorrect normal values.  Reclassifying the spirometry from 
one of the sites with normal values for the Western Indian population (20), reduced the 
proportion of restrictive spirometry from 33.0% to 12.2%.  In countries where normal values 
are not well defined, surveys should recruit enough participants to enable calculation of 
normal values from asymptomatic individuals. Evolving understanding of this non-specific 
restrictive spirometry – recently designated as ‘preserved ratio-impaired spirometry’ (PRISm) 
suggests that about a quarter will progress over time to diagnosed respiratory disease (27). 
Risk factors for PRISm applicable to our population include post-TB and biomass fuel 
exposure. A prevalence of 12.2% is comparable to that described in other studies (27,28). 
We faced a number of practical challenges, including a concern that the available translations 
of the questionnaires needed to be explained in the local dialect. Quality control is important 
in training for performing spirometry, with on-going oversight to maintain standards (29). 
Future studies should take into account the timing of data collection and adapt to the local 
context, such as not recruiting during Ramadan or on weekdays, when recruitment was 
difficult. Engaging communities and village leaders would help to facilitate recruitment 
process by advising on timing, and improving access. 
 
Conclusion 
Our consensus-derived gold-standard diagnosis enabled us to determine predictors of 
asthma, COPD, restrictive lung conditions, PRISm and ‘other CRD’ from the data collected in 
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a questionnaire survey and spirometry at five sites in South/South East Asia. Detecting asthma 
in population surveys relies on symptoms and history and our findings may be used to derive 
predictive values for use in large-scale surveys. In contrast, spirometry is the basis for 
detecting COPD, possibly supported by participant demographic information. However, 
ensuring adequate sample size  to determine local normal spirometry values is important. 
Despite the challenges of conducting surveys on CRDs in LMICs, accurate and reliable data on 
prevalence and impact on individuals, their families and communities are needed to inform 
healthcare policy on prioritising care and targeting risk factors such as smoking and poor air 
quality to reduce avoidable morbidity and mortality. 
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Table 1. Characteristics of sites and arrangements for the survey 
COUNTRY  
Site, Locality 










65 Km north 
of Dhaka  
Computer generated random 
sample of adults residing in 
Mirzapur Upazila from 
Demographic Surveillance System 
(DSS) database 
 
Although there had been a BOLD-1 site 
in Dhaka, the Bangladesh site was 
unable to obtain the Bengali version.   
The site used forward and backward 
translation process to translate the 










Computer generated random 
sample of adults residing in 18 
rural Peripheral Service Units in the 
Rural Unit for Health and Social 
Affairs (RUHSA) population 
database. 
The BOLD questionnaire is available in 
Tamil language. However, the local 
dialect used in the rural site is 
significantly different from standard 
Tamil, so the researchers had to 
explain/adapt specific words to ensure 
the questionnaire was understood by 











Computer generated random 
sample of adults residing in the 
Junnar block in the Health and 
Demographic Surveillance System 
(HDSS) database 
The BOLD questionis available in 
Marathi language, and had been 
translated locally and used previously 








The Department of Statistics 
Malaysia randomly selected 200 
Living Quarters in the Klang 
District, randomly sampled one 
household within each quarter, 
and then randomly selected one 
member of the household to be 
surveyed to a total of 101 
participants 
The site used the English and Malay 
versions, as preferred by the participant. 
The BOLD questionnaire was available in 
Malay language, but there were 
concerns about local appropriateness of 
the translation.   The site used forward 
and backward translation process to 
translate the English questions to the 
Malay language. 
PAKISTAN 
Allergy & Asthma 
Institute (AAAI), 
Islamabad. 




Randomly selected areas within 
Islamabad and Rawalpindi and 
then randomly selected adults 
from the population census lists of 
those areas 
 
The BOLD questions are available in 
Urdu language. However, the local 
dialect used is significantly different 
from standard Urdu,  so the researchers 
had to explain/adapt specific words to 
ensure the questionnaire was 
understood by local communities 
Note:  The RESPIRE study questionnaire was adapted with permission from BOLD-1 [12]  with the addition of eight asthma-
related questions from ECRHS-II [13]. 
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Table 2. Diagnostic categories 
Diagnostic category Description Gold standard 
diagnosis 
N = 508 
COPD COPD based on obstructive spirometry (CRD symptoms and 
FEV1/FVC < LLN).    Clinical discretion was allowed if FEV1/FVC 
fell between LLN and fixed ratio of 70% according to 
symptoms/risk factors. 
COPD 23 
Asthma (spirometry) Asthma based on spirometry: obstructive spirometry with 
substantial BD reversibility (increase in FEV1 of >15% and 
>400mls)(19) 
Asthma 8 
Asthma (symptoms) Asthma based on a number of symptoms, self-reported 
physician diagnosis, atopic co-morbidities, and family history: 
spirometry normal 
75 
Other CRD Other Chronic Respiratory Disease (post-TB, 
bronchiectasis/chronic bronchitis with normal spirometry) 
Other CRD 15 
RLD Restrictive Lung Disease: restrictive spirometry (FVC<80% and 
FEV1/FVC >LLN) with one or more CRD symptom 
RLD 65 
No CRD Asymptomatic and normal spirometry  No CRD 192 
Isolated symptom 
(CRD unlikely) 
Isolated symptom that could be due to CRD (usually asthma) 
but no other evidence of CRD and normal spirometry.   
CRD unlikely  42 
Restrictive 
(asymptomatic) 





Non-respiratory Symptoms likely to be due to a non-respiratory cause (e.g. 




Unclear Unclear symptoms; uninterpretable spirometry Unclear 12 
Abbreviations:  COPD:  Chronic Obstructive Pulmonary Disease; CRD: Chronic Respiratory Disease; FEV1:  Forced Expiratory 
Volume in 1 second;  FVC: Forced Vital Capacity;  LLN:  Lower Limit of Normal;  BD: Bronchodilator;  RLD:  Restrictive Lung 
Disease 
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Table 3: Characteristics of the study population 
COUNTRY  
(Site, Locality) 





















43 (43) 44.7 (14.6) 24.6 (4.5) 28 (28) 71 (70) 90 (89) 51 (51) 
INDIA (CMC)  
N=100 
42 (42) 43.6 (10.8) 25.4 (4.9) 9 (9) 77 (77) 95 (95) 36 (36) 
INDIA (KEMHRC) 
N=106 
52 (49) 41.8 (16.3) 22.3 (4.0) 5 (5) 14 (13) 75 (71) 50 (47) 
MALAYSIA  (UM) 
N=101 
51 (50) 44.0 (14.5) 25.7 (5.2) 30 (30) 33 (33) 0 (0) 65 (64) 
PAKISTAN (AAI) 
N=100 
57 (57) 36.3 (13.4) 25.9 (6.3) 28 (28) 19 (19) 16 (16) 82 (82) 
1  ‘Ever smoked’ is a positive response to Q1028: Have you ever smoked cigarettes?  
2  ‘Dusty job’ is a positive response ‘to Q1034: Have you ever worked for a year or more in a dusty job? 
3  ‘Biomass cooking’ is a positive response to Q1057: Has an indoor open fire with wood, crop residues or dung 
been used as a primary means of cooking in your home for more than 6 months in your life? 
Note: The differences in characteristics between the sites are likely to be due the small sample sizes in this 
feasibility study rather than real differences in populations that would have been captured in a fully powered 
survey with approximately 100 participants/site.   
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Table 4: Parameter estimates for a predictive models for asthma and COPD 




Did not have wheezing in the last 12 months -0.4217 
Had wheezing in the last 12 months 0.3741 
Never had trouble with breathing -0.1881 
Had trouble with breathing 0.1608 
Not woken up with a feeling of tightness [ECRHS II] -0.5401 
Woken up with a feeling of tightness [ECRHS II] 0.4829 
Not had an attack of SoB that came on following strenuous activity at any 
time in the last 12 months [ECRHS II] 
-0.3810 
Had an attack of SoB that came on following strenuous activity at any time 
in the last 12 months [ECRHS II]} 
0.3354 
Have not been woken by an attack of coughing at any time in the last 12 
months [ECRHS II]} 
-0.2323 
Have been woken by an attack of coughing at any time in the last 12 months 
[ECRHS II]} 
0.2006 
No nasal allergy -0.0085 










Note: Confidence intervals around the parameter estimates are not automatically generated in lasso regression; our focus 
was mainly on developing a reliable predictive model of asthma and COPD that could be used in future surveys. 
Abbreviations:  ECRHS: European Community Respiratory Health Survey; SoB: Short of Breath; COPD:  Chronic Obstructive 
Pulmonary Disease; FEV1:  Forced Expiratory Volume in 1 second;  FVC: Forced Vital Capacity;   
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Table 5: Barriers and challenges to conducting the survey 
 Barriers and challenges as described by researchers 
Questionnaire 
development 
Some validated translations were unclear, and questions used expressions that needed 
translating into the local dialect or concepts that needed to be explained by 
researchers.   Specifc examples include, the Tamil word for a ‘cold’ (viral upper 
respiratory infection) was corrected from ‘thadiman’ (which translates as ‘thickness’) to 
‘jalathoṣam’.  The word ‘Vaithiyar’ (used for unqualified ‘doctors’) was changed to 
‘Maruthuvar’.   In some dialects of Indian vernacular language there is no specific term 
for asthma, and in Malay the local term 'lelah' denotes both asthma and COPD. 
Maintaining 
quality of  
spirometry  
There were few existing trained spirometry technicians, so sites needed to train 
research assistants to conduct spirometry. Additional training was needed to maintain 
quality especially regarding  importance of performing an inspiratory loop.  
Turnover of research assistants necessitated repeated training 
Barriers to data 
collection  
Variable working hours of potential participants on weekdays meant that surveys 
needed to be conducted in evenings/weekends.     
Data collection coincided with Ramadan making it difficult to recruit in Muslim 
communities   
Language barriers when communicating with participants of different ethnicity (e.g in 
Malaysia which has three ethnic groups and languages) during recruitment may have 
led to participants’ refusal.  
Cultural norms (e.g. the need to refer to the head of family for a decision to participate)  
Reluctance of participants to attend the clinic review 
Enumerator 
safety  
Safety was a concern in some areas with need for research assistants to work in groups  
Societal fear of crime, dogs,  harassment 
Insurance for the research team was costly 
 




Figure 1: Clinical diagnostic schema 
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Figure 2: ROC curve showing sensitivity against specificity for model predicted values 
compared with the goldstandard asthma diagnosis 
